Adaptimmune Therapeutics Plc (ADAP) - Total Liabilities

Latest as of June 2025: $201.59 Million USD

Based on the latest financial reports, Adaptimmune Therapeutics Plc (ADAP) has total liabilities worth $201.59 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ADAP asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Adaptimmune Therapeutics Plc - Total Liabilities Trend (2011–2024)

This chart illustrates how Adaptimmune Therapeutics Plc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Adaptimmune Therapeutics Plc.

Adaptimmune Therapeutics Plc Competitors by Total Liabilities

The table below lists competitors of Adaptimmune Therapeutics Plc ranked by their total liabilities.

Company	Country	Total Liabilities
Polar Capital Holdings plc LSE:POLR	UK	GBX97.30 Million
Prismaflex Intl PA:ALPRI	France	€24.84 Million
Ming Shing Group Holdings Ltd NASDAQ:MSW	USA	$10.40 Million
Tempo Inti Media Tbk JK:TMPO	Indonesia	Rp206.41 Billion
Culpeo Minerals Ltd AU:CPO	Australia	AU$133.18K
Duketon Mining Ltd AU:DKM	Australia	AU$349.57K
Clinical Laserthermia Systems AB (publ) ST:CLS-B	Sweden	Skr22.07 Million
Zhuhai Sailong Pharmaceutical Co Ltd SHE:002898	China	CN¥477.34 Million

Liability Composition Analysis (2011–2024)

This chart breaks down Adaptimmune Therapeutics Plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Adaptimmune Therapeutics Plc net asset quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.52	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-2.84	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	1.54	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Adaptimmune Therapeutics Plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Adaptimmune Therapeutics Plc (2011–2024)

The table below shows the annual total liabilities of Adaptimmune Therapeutics Plc from 2011 to 2024.

Year	Total Liabilities	Change
2024-12-31	$234.11 Million	-3.70%
2023-12-31	$243.10 Million	-1.59%
2022-12-31	$247.04 Million	-6.28%
2021-12-31	$263.58 Million	+139.81%
2020-12-31	$109.92 Million	+89.82%
2019-12-31	$57.91 Million	+93.98%
2018-12-31	$29.85 Million	-61.81%
2017-12-31	$78.16 Million	+14.32%
2016-12-31	$68.37 Million	+66.48%
2015-12-31	$41.07 Million	0.00%
2014-12-31	$41.07 Million	-22.67%
2013-12-31	$53.11 Million	+1239.03%
2012-12-31	$3.97 Million	-3.03%
2011-12-31	$4.09 Million	--

About Adaptimmune Therapeutics Plc

NASDAQ:ADAP USA Biotechnology

Market Cap

$9.54 Million

Market Cap Rank

#27276 Global

#5640 in USA

Share Price

$0.04

Change (1 day)

-29.13%

52-Week Range

$0.04 - $0.22

All Time High

$14.16